This recent study examined a subpopulation of luminal progenitors secretes pleiotrophin to promote angiogenesis and metastasis in #InflammatoryBreastCancer , read it here👇
Filipa Lynce, MD, FASCO #IBC
pubmed.ncbi.nlm.nih.gov/38507720/

Inflammatory breast cancer didn’t stop scuba diver Stephanie Lafontaine from pursuing her passions. Learn more about how Stephanie’s care team helped her reach remission + kept her exploring the ocean depths.

ms.spr.ly/6016c4e2M

#inflammatorybreastcancer #breastcancer

The OXEL trial, led by Filipa Lynce, MD, FASCO, is out on Nature Communications. Among 45 pts with residual TNBC after NAT, adjuvant nivo/cape were well tolerated, increased peripheral immune score & led to numerically improved 2y iDFS (91%) vs nivo (47%) or cape alone (53%). nature.com/articles/s4146…

Stephanie Lafontaine is never more at peace than when deep below the water’s surface. Even if she’s sharing the depths with sharks, she considers it her happy place.

#breastcancer

ms.spr.ly/6010cUmga

One of my key research efforts is to expand the benefit of ADCs to pts with rare BC forms. On #RareDiseaseDay , I’d like to highlight 2 trials I had the chance to develop w/ Filipa Lynce, MD, FASCO & Dr Sarah Sammons:
-TRUDI➡️T-DXd/Durva for IBC
-DATO-Base➡️Dato-DXd for BCBM + LMD
Both enrolling!

Addressing Residual Disease in #HER2 + and #TripleNegativeBreastCancer : What Is Next?
New #TNBC review in Current Oncology Reports from
Ilana Schlam #JoshuaDower Filipa Lynce, MD, FASCO
👉pubmed.ncbi.nlm.nih.gov/38393609/

Our #InflammatoryBreastCancer program led by Dr. Lynce (Filipa Lynce, MD, FASCO) is dedicated to providing comprehensive treatment and novel research. In addition to launching clinical trials and a patient registry we have established an #IBC Awareness Day (2nd Tues of Oct). #RareDiseaseDay

Let's celebrate #RareDiseaseDay by racing toward a cure for Inflammatory Breast Cancer. Join Team IBC The Jimmy Fund to raise much needed funds for IBC research and patient care! danafarber.jimmyfund.org/goto/TeamIBC20…
Antonio Giordano, MD PhD Paolo Tarantino Laura Warren, MD Dana-Farber’s Breast Oncology Center Meredith Regan, ScD Filipa Lynce, MD, FASCO

KEYNOTE-522 outcomes by RCB out on Annals of Oncology. Largest benefit from pembro was observed in the RCB-2 group. Striking difference in 3-year EFS between RCB-1 (≃84%) and RCB-3 (≃30%): not all residual disease is created equal! annalsofoncology.org/article/S0923-…

'From serendipity to intention: development of brain penetrant PARP1 selective inhibitors' - recent commentary from Dr. Filipa Lynce (Filipa Lynce, MD, FASCO) and Dr. Nancy Lin (@nlinmd).
pubmed.ncbi.nlm.nih.gov/38251977/

We are thrilled to see our IBC clinical trial study is officially out in BreastCancerResearch. We found the use JAK1/2 inhibitor Ruxolitinib in TN-IBC resulted in decreased pSTAT3 but lack of clinical benefits. Comb with immunotherapy may need to be considered.
…ast-cancer-research.biomedcentral.com/articles/10.11…

Stephanie Lafontaine, an #InflamatoryBreastCancer patient advocate and fundraiser, discusses her love of scuba diving, underwater photography, and our #IBC Program, currently led by Dr. Filipa Lynce (Filipa Lynce, MD, FASCO). Don't miss her story and her gorgeous underwater photos! 🐠🐡🐟

“Connecting to a team at Dana-Farber Brigham focused mainly on IBC gave me so much confidence,” says Stephanie. “I knew my treatment was going to benefit directly from research they were doing at Dana-Farber.” blog.dana-farber.org/insight/2024/0…

Come check our poster on the TRUDI phase 2 study, the first trial combining neoadjuvant T-DXd + IO to treat inflammatory breast cancer! Filipa Lynce, MD, FASCO Dana-Farber’s Breast Oncology Center Dana-Farber IBC Program #SABCS23

Dr. Filipa Lynce (Filipa Lynce, MD, FASCO), Director of Dana-Farber IBC Program, is moderating the #SABCS23 People’s Choice Education Session on #InflammatoryBreastCancer : Clinical Challenges, Evolving Concepts and Novel treatments.

Filipa Lynce, MD, FASCO moderating the inflammatory breast cancer (people’s choice) session in which pathology, surgery and radiation (@jenniferbellon2) issues will be discussed

#bcsm #SABCS2023 Dana-Farber IBC Program

#SABCS23 | Poster PO1-06-04| Immune checkpoint inhibitors for #TNBC (INCORPORATE): An international multicenter retrospective analysis.
Dario Trapani Sara Tolaney @filipalynce Carmine Valenza #DanaFarberSABCS23 G Curigliano MD PhD Wendy Woodward MDPhD Lisa Carey, MD, ScM, FASCO Gabriele Antonarelli Luca Boscolo Bielo

Come by and chat with Dr. Filipa Lynce (Filipa Lynce, MD, FASCO) and Dr. Nolan Priedigkeit (@npriedig) about their research on Comprehensive clinicogenomic characterization of #InflammatoryBreastCancer in today's Poster Session 1. #SABCS23 #DanaFarberSABCS23 #IBC #BreastCancer

Check out our Roadmap to IBC talks and poster presentations at SABCS 2023. We hope to see many of you at SABCS! @SABCS Dana-Farber IBC Program @teamoncolgoy IBCIC IBC Research Fdn The IBC Network Foundation Wendy Woodward MDPhD jennifer bellon Meredith Regan, ScD Filipa Lynce, MD, FASCO

IBC New England’s dedication to spreading awareness established a permanent IBC Awareness Day in Massachusetts. Thank You IBC NE for your continuous commitment to advocacy, research and education. We look forward to continuing our collaborative efforts in the fight against IBC.